MedTrace Logo

Transarterial Chemoembolization Plus Hypofractionnated Radiotherapy vs. Surgery in Locally Advanced Hepatocellular Carcinoma: an IPTW Comparison

NCT04823715 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 163

Last updated 2021-04-01

No results posted yet for this study

Summary

Patients with non-metastatic unresectable hepatocellular carcinoma

Conditions

  • Non-metastatic Hepatocellular Carcinoma

Interventions

OTHER

TACE + hypofractionated EBRT

One cure of doxorubicin or DC Beads transarterial chemoembolization by a highly experienced interventional radiologist, followed 1 to 4 weeks later by hypofractionated external beam radiation therapy up to a total dose of 45-60 Gy, 3 Gy per fraction, 5 fractions per week, for an overall treatment time of 3 to 4 weeks.

PROCEDURE

Surgical resection

Surgical resection by open-laparotomy or laparoscopy of hepatocellular carcinoma by a highly experienced liver surgeon

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-15
Primary Completion
2021-01-15
Completion
2021-01-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04823715 on ClinicalTrials.gov